Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 309-315

  Zemel, Michael B ^a,b   Bruckbauer, Antje ^a  

^a Sustainable Aviation Foundation   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Adiposity; Body composition; Caloric restriction; Fat loss; Leucine; Pyridoxine; Vitamin B6; Weight loss

Indexed keywords

LEUCINE; NUSHAPE; NUTRACEUTICAL; PLACEBO; PYRIDOXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LIPID OXIDATION; LONG TERM CARE; LOW CALORY DIET; MALE; NUTRITIONAL ASSESSMENT; OBESITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 84882801522     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S49623     Document Type: Article

References (35)

1. Sun X, Zemel M. Leucine and calcium regulate fat metabolism and energy partitioning in murine adipocytes and muscle cells. Lipids. 2007; 42:297-305.
2. Sun X, Zemel MB. Leucine modulation of mitochondrial mass and oxygen consumption in skeletal muscle cells and adipocytes. Nutr Metab (Lond). 2009;6:26.
3. Macotela Y, Emanuelli B, Bang AM, et al. Dietary leucine-an envrionmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One. 2011;6:e21187.
4. Donato J Jr, Pedrosa RG, Cruzat VF, Pires IS, Tirapegui J. Effects of leucine supplementation on the body composition and protein status of rats submitted to food restriction. Nutrition. 2006;22:520-527.
5. Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ, Yu YH. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes. 2007;56:1647-1654.
6. Bruckbauer A, Zemel MB. Effects of dairy consumption on SIRT1 and mitochondrial biogenesis in adipocytes and muscle cells. Nutr Metab (Lond). 2011;8:91.
7. Bruckbauer A, Zemel MB, Thorpe T, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012;9:77.
8. Zemel MB, Bruckbauer A. Effects of a leucine and pyridoxine-containing nutraceutical on fat oxidation, and oxidative and inflammatory stress in overweight and obese subjects. Nutrients. 2012;4:529-541.
9. Xue B, Zemel M. Relationship between human adipose tissue agouti and fatty acid synthase (FAS). J Nutr. 2000;130:2478-2481.
10. Kim J, Kiefer L, Woychik R, et al. Agouti regulation of intracellular calcium: role of melanocortin receptors. Am J Physiol. 1997;272: E379-E384.
11. Xue B, Greenberg A, Kraemer F, Zemel M. Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J. 2001;15:2527-2529.
12. Xue B. The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+-dependent mechanism. FASEB J. 1998;12:1391-1396.
13. Shi H, Moustaid-Moussa N, Wilkison W, Zemel M. Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J. 1999;13:1833-1838.
14. Rossmeislova L, Malisova L, Kracmerova J, et al. Weight loss improves adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes. 2013;62:1990-1995.
15. Olszanecka-Glinianowicz M, Chudek J, Szromek A, Zahorska-Markiewicz B. Changes of systemic microinflammation after weight loss and regain-a five-year follow up study. Endokrynol Pol. 2012; 63:432-438.
16. Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007;31:1442-1448.
17. Colon-Gonzalez F, Kim GW, Lin JE, Valentino MA, Waldman SA. Obesity pharmacotherapy: what is next? Mol Aspects Med. 2013;34: 71-83.
18. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol. 2012;57:91-97.
19. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008;37:635-646, viii-ix.
20. Medina-Gomez G. Mitochondria and endocrine function of adipose tissue. Best Pract Res Clin Endocrinol Metab. 2012;26:791-804.
21. Fujihara S, Mori H, Kobara H, et al. Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract. 2012;2012:483623.
22. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53:2490-2514.
23. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813: 1269-1278.
24. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056-1060.
25. Xu XJ, Pories WJ, Dohm LG, Ruderman NB. What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant? Curr Opin Lipidol. 2013;24:49-56.
26. Gauthier MS, O'Brien EL, Bigornia S, et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun. 2011;404: 382-387.
27. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, Young LH, Shulman GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 2001;50:1076-1082.
28. Pold R, Jensen LS, Jessen N, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes. 2005;54:928-934.
29. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3:403-416.
30. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109-1122.
31. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8:347-358.
32. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-1217.
33. Schriever SC, Deutsch MJ, Adamski J, Roscher AA, Ensenauer R. Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. J Nutr Biochem. 2013;24:824-831.
34. Stancliffe RA, Eades M, Smart K, Zemel MB. Role of mTOR and β-hydroxy-β-methylbutyrate (HMB) in leucine stimulation of muscle mitochondrial biogenesis and fatty acid oxidation. FASEB J. 2011; 25:601.1.
35. Stancliffe RA, Zemel MB. Role of β-hydroxy-β-methylbutyrate (HMB) in leucine stimulation of muscle mitochondrial biogenesis. FASEB J. 2012;26:251.6.